Actemra (tocilizumab) received emergency use authorization for the treatment of coronavirus disease 2019 (COVID-19) in June 2021. Literature has linked numerous cutaneous adverse effects to tocilizumab. In this current survey, investigators reviewed and compared these adverse effects to the common cutaneous manifestations of COVID-19. While similarities in patient presentation exist, important distinctions are made to aid dermatologists in their clinical diagnosis. J Drugs Dermatol. 2023;22(12):e42-e43. doi:10.36849/JDD.6532e.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.36849/JDD.6532 | DOI Listing |
Publication Analysis
Top Keywords
adverse effects
8
tocilizumab treatment
4
treatment covid-19
4
covid-19 patients
4
patients comparing
4
comparing cutaneous
4
cutaneous disease
4
disease adverse
4
adverse drug
4
drug effects
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!